Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y5TL
|
|||
| Former ID |
DNC005808
|
|||
| Drug Name |
Alloxazine
|
|||
| Synonyms |
Alloxazine; Isoalloxazine; 490-59-5; Alloxazin; benzo[g]pteridine-2,4(1H,3H)-dione; 1H-Benzo[g]pteridine-2,4-dione; Benzo(g)pteridine-2,4(1H,3H)-dione; UNII-880W3VF9YW; benzo[g]pteridine-2,4(3H,10H)-dione; CHEMBL68500; 880W3VF9YW; CHEBI:37325; HAUGRYOERYOXHX-UHFFFAOYSA-N; Benzo[g]pteridine-2,4[1H,3H]-dione; 1H,2H,3H,4H-benzo[g]pteridine-2,4-dione; Benzo[g]pteridine-2,3H)-dione; WLN: T C666 BN DMVMV INJ; 1,3-dihydrobenzo[g]pteridine-2,4-dione; SR-01000075199; Alloxazine, 96%; EINECS 207-714-3; NSC 203056; AC1NSYUA; Lopac-A-242
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H6N4O2
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)N=C3C(=N2)NC(=O)NC3=O
|
|||
| InChI |
1S/C10H6N4O2/c15-9-7-8(13-10(16)14-9)12-6-4-2-1-3-5(6)11-7/h1-4H,(H2,12,13,14,15,16)
|
|||
| InChIKey |
HAUGRYOERYOXHX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 490-59-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
451914, 473315, 4956928, 6156892, 7778045, 10523977, 10560890, 10589628, 11110697, 11216386, 11402151, 11657363, 15365357, 17404721, 17425201, 17425202, 24277695, 24890699, 25632054, 26753529, 39392322, 47331796, 48259515, 48259516, 48448037, 49645529, 50105899, 50105900, 53777264, 57362399, 80096949, 85083500, 85090530, 85208946, 85230889, 88297412, 88521338, 89449665, 90340898, 92220724, 92225576, 92303577, 99017118, 99226622, 103264398, 104839904, 105206877, 114174506, 121361102, 124504616
|
|||
| ChEBI ID |
CHEBI:37325
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A2a receptor (ADORA2A) | Target Info | Inhibitor | [2] |
| Adenosine A2b receptor (ADORA2B) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Alcoholism | ||||
| cAMP signaling pathway | ||||
| Parkinson's disease | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Pathway Interaction Database | C-MYB transcription factor network | |||
| HIF-2-alpha transcription factor network | ||||
| Reactome | Adenosine P1 receptors | |||
| G alpha (s) signalling events | ||||
| Surfactant metabolism | ||||
| NGF-independant TRKA activation | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Monoamine Transport | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 456). | |||
| REF 2 | 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.